Tollys is a biopharmaceutical company focused on innate immunity, particularly on the biology and modulation of the TLR3 receptor.
Tollys has raised €2.3M across 1 funding round, most recently a Series A round in May 2020. Based in Lyon, France; founded 2015; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2020-05-26 | Series A | €2.3M |
| — |
| View deal → |
